Nutritional Products was the largest of Abbott Laboratories’s 5 reported lines in fiscal 2016, at $6.90B — 33% of $20.85B.
| Statement Business Segments | FY 2009 | FY 2010 | FY 2011 | FY 2013 | FY 2014 | FY 2015 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Revenue, Net | — | — | — | — | |||
| Nutritional Products | $6.74B | $6.95B | $6.98B | $6.90B | |||
| Salesrevenuenet | — | — | — | — | |||
| Diagnostic Products | $4.55B | $4.72B | $4.65B | $4.81B | |||
| Established Pharmaceutical Products | $2.86B | $3.12B | $3.72B | $3.86B | |||
| Vascular Products | $3.01B | $2.99B | — | — | |||
| Cardiovascular & Neuromodulation Products | — | — | $2.79B | $2.90B | |||
| Other | $2.50B | $2.47B | $2.27B | $2.39B | |||
| Total | $19.66B | $20.25B | $20.41B | $20.85B |
In fiscal 2016, which ended December 31, 2016, the 5 segments Abbott Laboratories reported in this breakdown added up to $20.85B. That was up 2.2% from $20.41B in fiscal 2015. Nutritional Products was the largest segment, at $6.90B or 33.1% of the total, followed by Diagnostic Products ($4.81B, 23.1%) and Established Pharmaceutical Products ($3.86B, 18.5%). Together, the two largest segments made up 56.2% of this total.
Compared with fiscal 2015, Other grew the fastest, rising 5.0% to $2.39B. Nutritional Products fell the most, down 1.1% to $6.90B.
Cardiovascular & Neuromodulation Products was first reported as a separate segment in fiscal 2015. The table also keeps 3 segments that Abbott Laboratories no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers 7 fiscal years between 2009 and 2016, as reported in Abbott Laboratories' annual filings.
United States was the largest of Abbott Laboratories’s 16 reported lines in fiscal 2017, at $9.67B — 35% of $27.39B.
| Geography | FY 2010 | FY 2011 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|
| United States | $6.12B | $6.27B | $6.49B | $9.67B | |||
| Salesrevenuenet | — | — | — | — | |||
| Revenue, Net | — | — | — | — | |||
| All Other Countries | $5.32B | $4.55B | $7.96B | $5.74B | |||
| China | $1.32B | $1.80B | $1.73B | $2.15B | |||
| Germany | $978.00M | $1.00B | $1.04B | $1.37B | |||
| Japan | $968.00M | $895.00M | $924.00M | $1.26B | |||
| The Netherlands | $788.00M | $855.00M | $830.00M | $929.00M | |||
| India | $1.01B | $1.05B | $1.11B | $1.24B | |||
| United Kingdom | $447.00M | $430.00M | $377.00M | $498.00M | |||
| Switzerland | $707.00M | $784.00M | $766.00M | $841.00M | |||
| France | — | $375.00M | $352.00M | $628.00M | |||
| Italy | $436.00M | $383.00M | $365.00M | $507.00M | |||
| Canada | $462.00M | $428.00M | $408.00M | $443.00M | |||
| Russia | $536.00M | $483.00M | $554.00M | $664.00M | |||
| Brazil | $508.00M | $381.00M | $410.00M | $541.00M | |||
| Vietnam | $357.00M | $331.00M | $434.00M | $427.00M | |||
| Colombia | $283.00M | $388.00M | $424.00M | $494.00M | |||
| Total | $20.25B | $20.41B | $24.18B | $27.39B |
In fiscal 2017, which ended December 31, 2017, the 16 regions Abbott Laboratories reported in this breakdown added up to $27.39B. That was up 13.3% from $24.18B in fiscal 2016. United States was the largest region, at $9.67B or 35.3% of the total, followed by All Other Countries ($5.74B, 21.0%) and China ($2.15B, 7.8%). Together, the two largest regions made up 56.3% of this total.
Compared with fiscal 2016, France grew the fastest, rising 78.4% to $628.00M. All Other Countries fell the most, down 27.9% to $5.74B.
The table also keeps 2 regions that Abbott Laboratories no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 7 fiscal years between 2010 and 2017, as reported in Abbott Laboratories' annual filings.
Abbott Laboratories (ABT) breaks its revenue down by segment and region. In fiscal 2016, its largest segment was Nutritional Products, with $6.90B or 33.1% of the total, followed by Diagnostic Products at $4.81B (23.1%).
Nutritional Products was Abbott Laboratories' largest segment in fiscal 2016, with $6.90B in revenue, 33.1% of the $20.85B reported across its 5 segments.
United States was Abbott Laboratories' largest region in fiscal 2017, with $9.67B in revenue, 35.3% of the $27.39B reported across its 16 regions.
Of the Abbott Laboratories segments reported in both fiscal 2015 and fiscal 2016, and making up at least 2% of the total, Other grew the fastest, rising 5.0% from $2.27B to $2.39B.
Every figure is taken from Abbott Laboratories' annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2009 to 2016. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.